Get started
Author

Gema García Ledo

Observed names: G. Garcia Ledo, G. García Ledo, G.M. Garcia Ledo, Gema Garcia Ledo, Gema Maria Garcia Ledo
ORCID: 0000-0002-7772-6876
Observed ORCID: 0000-0002-7772-6876
OpenAlex ID: A5020985643
Lung cancer patients with COVID-19 in Spain: GRAVID study
2021 · Mariano Provencio, José María Mazarico Gallego, et al. · Lung Cancer · 40
PDF
A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population.
2022 · Enriqueta Felip, Margarita Majem, et al. · Journal of Clinical Oncology · 25
1312MO Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (phase II)
2023 · E. Carcereny, E. Felip, et al. · Annals of Oncology · 5
PDF
Achieving complete metabolic response in stage IV lung adenocarcinoma with chemotherapy, nivolumab, ipilimumab, and salvage SBRT : A case report
2024 · Salvador Gamez Casado, Javier David Benitez Fuentes, et al. · Respirology Case Reports · 4
PDF
Eftilagimod Alpha Plus Pembrolizumab in First-Line Metastatic Non–Small Cell Lung Cancer: Results From a PD-L1–Unselected Population in the TACTI-002 Study
2025 · Margarita Majem, Enric Carcereny, et al. · JCO oncology advances. · 3
PDF
1470 Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 (Phase II)
2022 · Wade Iams, Enriqueta Felip, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
Patient-derived lung cancer organoids for the selection of therapeutic options in an ALK-rearranged tumor.
2021 · Beatriz Jimenez Munarriz, Zahra Dantes, et al. · Journal of Clinical Oncology · 2
Real-World Insights into Stage I–III Non-Small Cell Lung Cancer in Spain in the Pre-Immunotherapy Era Using AI Techniques: The IntellyLUNG Study
2026 · Jesús Corral Jaime, Javier de Castro, et al. · Life · 1
PDF
Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC
2023 · Zoran Andric, Gabriella Gálffy, et al. · JTO Clinical and Research Reports · 1
24P Tepotinib in patients with MET exon 14 skipping NSCLC: Efficacy and safety by line of therapy
2022 · F. Griesinger, E. Felip, et al. · Annals of Oncology · 1
PDF
P2.08.37 Neoadjuvant Chemoimmunotherapy in Resectable NSCLC. Real-World Evidence From a Spanish Multicenter Cohort
2025 · K. Medina Sanchez, C. Cabrera, et al. · Journal of Thoracic Oncology
595 Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab
2023 · Martin Forster, Enriqueta Felip, et al. · Journal for ImmunoTherapy of Cancer
PDF
12P Molecular features of KRAS mutant NSCLC: Weaving a future score for immune-checkpoint inhibitors (ICI)
2021 · M. Dorta Suarez, B. Jimenez Munarriz, et al. · Annals of Oncology
PDF
COVID-19 disease in patients with LUNG cancer in Spain: GRAVID LunG canceR pAtients coVid19 Disease (GRAVID STUDY).
2021 · Mariano Provencio, Jose Maria Mazarico, et al. · Journal of Clinical Oncology
Abstract S12-04: COVID-19 disease in patients with lung cancer in Spain: GRAVID Lung Cancer Patients Disease (GRAVID study)
2021 · Jose Maria Mazarico Gallego, Antonio Calles, et al. · Clinical Cancer Research
Tratamiento del cáncer de próstata hormonorrefractario
2004 · J.L. González-Larriba, Gema García Ledo · Revisiones en cáncer
Works count: 16
Citation count: 85
H-index: 4
I10-index: 2
Year
Topic
Type